How should psoriatic arthritis be managed in women, including treatment options, monitoring, and special considerations for pregnancy, conception, and breastfeeding?

Management of Psoriatic Arthritis in Women

Women with psoriatic arthritis should be treated according to disease severity with a treat-to-target approach aiming for remission or low disease activity, with treatment selection critically dependent on pregnancy planning status—methotrexate and leflunomide are absolutely contraindicated in pregnancy and must be stopped 1-3 months and require cholestyramine washout respectively before conception, while TNF inhibitors (particularly certolizumab), hydroxychloroquine, sulfasalazine, and azathioprine can be continued or used during pregnancy when needed. 1, 2, 3

Treatment Algorithm by Disease Severity

Peripheral Arthritis Management

For polyarthritis with active disease:

• Initiate a conventional synthetic DMARD (csDMARD) rapidly
• Methotrexate is preferred when significant skin involvement is present 1
• However, in women of childbearing potential, methotrexate requires strict contraception and must be discontinued 1-3 months before planned conception 4, 2, 3

For monoarthritis or oligoarthritis:

• Consider csDMARD if poor prognostic factors present (structural damage, elevated ESR/CRP, dactylitis, nail involvement) 1
• NSAIDs and local glucocorticoid injections may be used for symptom relief 1

For inadequate response to at least one csDMARD:

• Advance to biologic DMARD (bDMARD)
• When relevant skin involvement exists, IL-17 inhibitors or IL-12/23 inhibitors may be preferred 1
• If bDMARDs fail or are inappropriate, consider JAK inhibitors 1

Enthesitis and Axial Disease

For unequivocal enthesitis:

• NSAIDs or local glucocorticoid injections first-line
• If insufficient response, advance to bDMARD 1

For predominantly axial disease:

• NSAIDs first-line
• If insufficient response, advance to bDMARD 1

Critical Pregnancy and Conception Considerations

Pre-Conception Planning

Absolutely contraindicated medications that must be stopped:

• Methotrexate: Stop 1-3 months before conception 2, 3
• Leflunomide: Stop and perform cholestyramine washout 2, 3
• Acitretin: Cannot be used in women who may become pregnant within 3 years of discontinuation 4
• Mycophenolate: Discontinue before conception 2, 3

Compatible medications for women planning pregnancy:

• Hydroxychloroquine: Continue 2, 3
• Sulfasalazine: Continue 2, 3
• Azathioprine: Continue 2, 3
• Colchicine: Continue 2, 3
• Certolizumab (TNF inhibitor): Preferred biologic—can continue throughout pregnancy 2, 3
• Other TNF inhibitors (adalimumab, etanercept, infliximab): Can continue through conception, then discontinue in third trimester several half-lives prior to delivery 2, 3

During Pregnancy

The primary concern is balancing maternal disease control against fetal safety—uncontrolled disease activity itself poses risks including preterm birth and cesarean delivery. 5, 6

Safe treatment options during pregnancy:

• Certolizumab: Can continue throughout entire pregnancy 2, 3
• Other TNF inhibitors: Continue in first and second trimesters; discontinue in third trimester 2, 3
• Hydroxychloroquine, sulfasalazine, azathioprine: Continue 2, 3
• Prednisone/prednisolone: Use at lowest effective dose, taper to <20 mg/day 2, 3
• Cyclosporine, tacrolimus: Can be used with blood pressure monitoring 2, 3
• NSAIDs: Continue in first and second trimesters; discontinue in third trimester 2, 3

Medications to avoid during pregnancy:

• IL-17 inhibitors, IL-12/23 inhibitors, JAK inhibitors: Limited safety data; discontinue at conception unless life-/organ-threatening disease 2, 3

Disease Activity During Pregnancy

Important counseling points:

• Joint disease shows variable course during pregnancy (58.5% improve or remain stable low activity) 7
• Skin disease typically improves during pregnancy (88% improve or stable low) 7
• Postpartum flares are common: 40% experience worsening or stable high joint activity, 43% experience skin worsening 7
• Plan for intensified monitoring postpartum 6, 7

Breastfeeding

Compatible medications during lactation:

• Hydroxychloroquine, sulfasalazine, colchicine, azathioprine: Compatible 2, 3
• NSAIDs: Compatible (ibuprofen preferred) 2, 3
• Prednisone: Low transfer; after doses >20 mg, delay breastfeeding 4 hours 2, 3
• All TNF inhibitors: Compatible with breastfeeding 2, 3
• Cyclosporine, tacrolimus: Low transfer 2, 3
• All bDMARDs are considered compatible due to large molecular size and minimal transfer 2, 3

Not recommended during breastfeeding:

• Methotrexate: Limited data suggest low transfer but avoid 2, 3
• Leflunomide: Not compatible 2, 3

Monitoring Requirements

Baseline assessment before initiating biologics:

• Complete blood count with platelets
• Comprehensive metabolic panel with liver function tests
• Hepatitis B and C panel
• Tuberculosis testing (interferon-gamma release assay or tuberculin skin test)
• Age-appropriate health maintenance 4

During treatment:

• Regular disease activity assessment to guide treat-to-target approach 1
• Monitor for infections, particularly granulomatous infections with TNF inhibitors 8
• For methotrexate (if used in non-pregnant patients): Monitor for hepatotoxicity; prior guidelines suggested liver biopsy after 1.5g cumulative dose 4

Special Populations and Pitfalls

Common pitfalls to avoid:

• Failing to discuss pregnancy planning early: All women of childbearing potential should receive counseling about medication compatibility before starting treatment 9
• Automatically treating mild psoriatic arthritis with TNF inhibitors: Patients without radiographic changes, loss of range of motion, or interference with daily living should not automatically receive TNF inhibitors; NSAIDs or rheumatology consultation for other options is reasonable 4
• Stopping all medications during pregnancy: This can lead to severe disease flares; many medications are compatible and should be continued 2, 3
• Not planning for postpartum monitoring: Disease frequently flares postpartum, requiring intensified surveillance 7

Obesity considerations:

• Methotrexate carries increased hepatotoxicity risk in overweight patients with likely steatohepatitis 8
• Infliximab and ustekinumab are weight-based, potentially advantageous for obese patients 8

First pregnancy considerations:

• Risk of preterm birth is primarily increased in first pregnancies in women with PsA 5
• Provide individualized monitoring, especially for primiparous women

Multidisciplinary collaboration:

• Rheumatologists should primarily manage musculoskeletal manifestations 1, 10
• Collaborate with dermatology for significant skin involvement 1, 10
• Coordinate with maternal-fetal medicine for pregnancy management 9